| Rank | Company | Headquarters | 2021 Revenues ($USD) |
|---|---|---|---|
| 1 | Pfizer | United States | $81,288,000,000 |
| 2 | Sinopharm (pharmaceutical distribution segment) | China | $60,450,609,227 |
| 3 | AbbVie | United States | $56,197,000,000 |
| 4 | Janssen (Johnson & Johnson’s pharmaceutical segment) | United States | $52,080,000,000 |
| 5 | Novartis | Switzerland | $51,626,000,000 |
| 6 | Roche Pharmaceuticals (division of Roche Group) | Switzerland | $49,257,436,570 |
| 7 | Merck & Co. | United States | $48,704,000,000 |
| 8 | GlaxoSmithKline (GSK) (minus consumer segment) | United Kingdom | $46,940,864,000 |
| 9 | Bristol Myers Squibb | United States | $46,385,000,000 |
| 10 | Sanofi | France | $44,557,980,000 |
| 11 | AstraZeneca | United Kingdom | $37,417,000,000 |
| 12 | Thermo Fisher Scientific (Life Sciences Solutions + Laboratory Products and Biopharma Services) | United States | $30,493,000,000 |
| 13 | Takeda Pharmaceutical | Japan | $29,113,364,894 |
| 14 | Eli Lilly | United States | $28,318,400,000 |
| 15 | Gilead Sciences | United States | $27,305,000,000 |
| 16 | Amgen | United States | $25,979,000,000 |
| 17 | Boehringer Ingelheim | Germany | $24,391,094,000 |
| 18 | BioNTech | Germany | $22,449,436,100 |
| 19 | Novo Nordisk | Denmark | $22,420,382,166 |
| 20 | Bayer (Pharmaceuticals Division) | Germany | $21,651,820,000 |
| 21 | Sinovac | China | $19,400,000,000 |
| 22 | Merck KGaA, Darmstadt, Germany (life sciences plus healthcare revenue) | Germany | $18,973,220,000 |
| 23 | Moderna | United States | $18,471,000,000 |
| 24 | Viatris | United States | $17,813,600,000 |
| 25 | Regeneron Pharmaceuticals | United States | $16,071,700,000 |
| 26 | Teva Pharmaceutical Industries | Israel | $15,878,000,000 |
| 27 | Astellas Pharma | Japan | $11,375,892,207 |
| 28 | Biogen | United States | $10,981,700,000 |
| 29 | CSL, including CSL Behring | Australia | $10,310,000,000 |
| 30 | Daiichi Sankyo | Japan | $9,512,855,062 |
| 31 | Chugai Pharmaceutical (Roche Group) | Japan | $9,101,957,393 |
| 32 | Otsuka Holdings (pharmaceutical business) | Japan | $8,899,380,918 |
| 33 | Bausch Health | Canada | $8,434,000,000 |
| 34 | Vertex Pharmaceuticals | United States | $7,573,000,000 |
| 35 | UCB | Belgium | $6,816,860,000 |
| 36 | Organon | United States | $6,304,000,000 |
| 37 | Lonza | Switzerland | $5,915,354,331 |
| 38 | Eisai | Japan | $5,880,371,449 |
| 39 | Grifols | Spain | $5,821,079,240 |
| 40 | Servier | France | $5,575,500,000 |
| 41 | Abbott (Established Pharmaceutical Products) | United States | $4,718,000,000 |
| 42 | Sumitomo Dainippon Pharma | Japan | $4,697,305,171 |
| 43 | Sun Pharmaceutical Industries | India | $4,530,743,855 |
| 44 | Sino Biopharmaceutical | China | $4,164,034,848 |
| 45 | Catalent | United States | $3,998,000,000 |
| 46 | WuXi AppTec | China | $3,550,317,030 |
| 47 | Ipsen | France | $3,385,302,000 |
| 48 | Aurobindo Pharma | India | $3,350,857,712 |
| 49 | Kyowa Kirin | Japan | $3,206,900,947 |
| 50 | Jazz Pharmaceuticals | Ireland | $3,094,238,000 |